• 5 December 2017

    Sonendo®, Inc., is pleased to announce that we have been named a Red Herring Top 100 Global winner for 2017.

  • 4 December 2017

    Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of bladder and bowel dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics seven new U.S. patents along with numerous foreign counterparts relating to its implantable sacral neuromodulation technology.

  • 1 December 2017

    InDex Pharmaceuticals Holding AB (publ) today announced new scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate. The findings show that cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response.

  • 28 November 2017

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting, medicines for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases, today announces successful results from its Phase 1/2a proof of concept study of TopiVert’s TOP1630 ophthalmic solution for the treatment of dry eye syndrome (DES). TOP1630 improved multiple symptom and sign endpoints in both an environmental setting and in the Controlled Adverse Environment (CAE®; Ora, Inc.) challenge. Furthermore, TOP1630 demonstrated excellent safety and placebo-like tolerability and comfort profiles.

  • 20 November 2017

    Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the closing of its initial public offering of 4,600,000 shares of its common stock at a public offering price of $10.00 per share, including 600,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option. The gross proceeds to Arsanis from the offering were $46.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares sold in the offering were offered by Arsanis. Arsanis’ shares began trading on The NASDAQ Global Market on November 16, 2017.